How does kratom work in the body?

Kratom works primarily through its active alkaloids, mitragynine and 7-hydroxymitragynine, which bind to mu-opioid receptors in the brain. This mechanism produces analgesic and sedative effects similar to opioids. At lower doses, the plant also interacts with adrenergic and serotonergic receptors, resulting in stimulant properties. While these pathways are identified in preclinical research, human clinical data remains limited (Evidence Level C).

Can you take kratom with prescription medications?

Kratom poses significant drug interaction risks. It should not be combined with CNS depressants like benzodiazepines, alcohol, or prescription opioids, as this combination can lead to dangerous respiratory depression. Additionally, kratom affects liver enzymes responsible for metabolizing many drugs. Due to limited safety data (Evidence Level C), individuals taking prescription medications should consult a healthcare provider before use.

What is a safe starting dosage for kratom?

Dosage is highly variable and depends on individual tolerance and desired effects. Generally, 1 to 5 grams of raw powder produces stimulant effects, while 5 to 15 grams induces sedation and pain relief. Because potency varies by strain and batch, and clinical guidelines are lacking (Evidence Level C), users should exercise extreme caution. High doses significantly increase the risk of adverse effects like seizures and dependence.

Is kratom safe to use during pregnancy?

No, kratom is considered unsafe during pregnancy and breastfeeding. The active compounds cross the placenta and can lead to neonatal abstinence syndrome, causing withdrawal symptoms in the newborn. Use during pregnancy is also associated with risks of fetal growth restriction. Due to the potential for serious harm, pregnant individuals should strictly avoid this herb.

Can kratom help with opioid withdrawal symptoms?

While anecdotal reports suggest kratom may alleviate opioid withdrawal symptoms, clinical evidence remains insufficient (Evidence Level C). Although mitragynine acts on opioid receptors, substituting one substance for another carries a risk of developing new dependence. Furthermore, the FDA has not approved kratom for treating opioid use disorder, and safety concerns regarding liver toxicity and seizures persist.

Kratom (Mitragyna speciosa)

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 27 articles PubMed · modèle : gemma4:31b

Résumé

Kratom (Mitragyna speciosa) is a tropical plant from Southeast Asia with psychoactive properties that produce analgesic, stimulant, and opioid-like effects [PMID:31643556, PMID:36256767].

Contexte

Kratom is an herbal product derived from the leaves of Mitragyna speciosa, a tropical evergreen tree native to Southeast Asia [PMID:31643556, PMID:36256767]. It is consumed globally as a tea, powder, or in capsules [PMID:36256767, PMID:28484399].

Usages traditionnels

Traditionally used in Southeast Asia and parts of Africa to increase the stamina of outdoor laborers, manage pain, treat diarrhea, and stave off fatigue [PMID:36256767, PMID:28484399, PMID:37364801].

Composés actifs

Kratom contains over 40 alkaloids [PMID:34775626, PMID:39640144]. The primary psychoactive compounds are mitragynine and 7-hydroxymitragynine [PMID:31643556, PMID:34775626]. Other identified compounds include corynantheidine and speciogynine [PMID:31643556, PMID:37518950].

Mécanisme d'action

Alkaloids in kratom interact with opioid (mu, delta, and kappa), adrenergic, serotonergic, and dopaminergic receptors [PMID:38217374, PMID:34775626, PMID:36594896]. Mitragynine and 7-hydroxymitragynine act as partial mu- and kappa-opioid agonists [PMID:31643556].

Preuves cliniques

Preuve BPain Management

Preclinical evidence and one randomized controlled trial support its therapeutic value as an analgesic [PMID:37266188].

Preuve COpioid Use Disorder/Withdrawal

Used as an alternative for treating opioid withdrawal symptoms and managing cravings [PMID:31999896, PMID:37266188].

Preuve DSleep

Bedtime use was associated with modest increases in self-reported sleep duration and quality in a 15-day study of adults [PMID:40839514].

Preuve CCognition

Mitragynine may adversely affect cognitive performances by disrupting synaptic plasticity and brain activity [PMID:39643045].

Sécurité et effets indésirables

Adverse effects include potential for dependence, withdrawal, and life-threatening toxicity [PMID:31999896]. Specific risks include acute liver injury and hepatotoxicity characterized by cholestatic patterns and perivenular necrosis [PMID:31643556, PMID:35399621, PMID:31919755]. Other reported effects include cardiotoxicity, seizures, psychosis, and cardiovascular, gastrointestinal, and psychiatric issues [PMID:34646135, PMID:28484399, PMID:35645563].

Grossesse et allaitement

In-utero exposure has raised concerns regarding the risk of neonatal abstinence syndrome [PMID:35645563]. Scientific evidence specific to therapeutic and adverse effects in pregnancy is limited to a few case reports [PMID:37679866].

Interactions médicamenteuses

Kratom's bioactive alkaloids can significantly impact the pharmacokinetics and pharmacodynamics of concomitant medications, though specific human drug interaction studies are limited [PMID:40522665, PMID:29255059].

Posologie et administration

Some individuals using kratom for chronic pain, depression, and anxiety typically consume 1-3 grams daily in powder form [PMID:39640144]. No PubMed data available. Consult a healthcare provider.

Synthèse des preuves

The evidence is primarily based on reviews, case reports, and preclinical data (Levels C and D), with very limited high-level clinical trial data (Level B).

Sources PubMed

1.PMID: 31999896 (2020) — Kratom (Mitragyna speciosa): Friend or Foe? · The primary care companion for CNS disorders
2.PMID: 38217374 (2024) — An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. · Expert review of clinical pharmacology
3.PMID: 31643556 (2012) — The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. · International journal of legal medicine
4.PMID: 36256767 (2026) — Kratom (Mitragyna speciosa): worldwide issues. · Current opinion in psychiatry
5.PMID: 35399621 (2022) — Kratom (Mitragyna speciosa)-Induced Hepatitis. · ACG case reports journal

Kratom

Sources et citations

Populus nigra

Black Pepper

Cumaru

Résumé

Contexte

Usages traditionnels

Composés actifs

Mécanisme d'action

Preuves cliniques

Sécurité et effets indésirables

Grossesse et allaitement

Interactions médicamenteuses

Posologie et administration

Synthèse des preuves

Sources PubMed

Sources gouvernementales

Kratom

Sources et citations

Plantes associées

Populus nigra

Black Pepper

Cumaru

Résumé

Contexte

Usages traditionnels

Composés actifs

Mécanisme d'action

Preuves cliniques

Sécurité et effets indésirables

Grossesse et allaitement

Interactions médicamenteuses

Posologie et administration

Synthèse des preuves

Sources PubMed

Sources gouvernementales